{"id":"short-acting-methylphenidate","safety":{"commonSideEffects":[{"rate":"10–20%","effect":"Insomnia"},{"rate":"10–15%","effect":"Decreased appetite"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Nervousness or anxiety"},{"rate":"5%","effect":"Tachycardia"},{"rate":"5%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters (DAT and NET) for dopamine and norepinephrine, leading to increased neurotransmitter concentration in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The short-acting formulation reaches peak plasma levels within 1–3 hours and has a duration of action of 3–5 hours.","oneSentence":"Short-acting methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:59.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT04823364","phase":"NA","title":"Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment","status":"TERMINATED","sponsor":"Weizmann Institute of Science","startDate":"2024-07-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":60},{"nctId":"NCT03709940","phase":"NA","title":"Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"King's College London","startDate":"2013-05-03","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":60},{"nctId":"NCT00863499","phase":"PHASE4","title":"International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder","status":"UNKNOWN","sponsor":"BRC Operations Pty. Ltd.","startDate":"2009-10","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":1344}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["• Ritalin","• Ritalina","• Attenta","• Methylin","• Penid"],"phase":"marketed","status":"active","brandName":"Short Acting Methylphenidate","genericName":"Short Acting Methylphenidate","companyName":"BRC Operations Pty. Ltd.","companyId":"brc-operations-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Short-acting methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}